text stringlengths 1 5.46k |
|---|
d) a brief in support of such Party's proposed rulings and remedies; provided that the brief shall not exceed 20 pages. This page limitation shall apply regardless of the number of issues raised in the ADR proceeding. |
Except as expressly set forth in subparagraphs 4(a) - 4(d), no discovery shall be required or permitted by any means, including depositions, interrogatories, requests for admissions, or production of documents. |
5. The hearing shall be conducted on two consecutive days and shall be governed by the following rules: |
a) Each Party shall be entitled to five hours of hearing time to present its case. The Neutral shall determine whether each Party has had the five hours to which it is entitled. |
b) Each Party shall be entitled, but not required, to make an opening statement, to present regular and rebuttal testimony, documents, or other evidence, to cross-examine witnesses, and to make a closing argument. Cross-examination of witnesses shall occur immediately after their direct testimony, and cross-examination... |
c) The Party initiating the ADR shall begin the hearing and, if it chooses to make an opening statement, shall address therein not only issues it raised but also any issues raised by the responding Party. The responding Party, if it chooses to make an opening statement, also shall address all issues raised in the ADR. ... |
d) Except when testifying, witnesses shall be excluded from the hearing until closing arguments. |
e) Settlement negotiations, including any statements made therein, shall not be admissible under any circumstances. Affidavits prepared for purposes of the ADR hearing also shall not be admissible. As to all other matters, the Neutral shall have sole discretion regarding the admissibility of any evidence. |
6. Within seven days following completion of the hearing, each Party may submit to the other Party and the Neutral a post-hearing brief in support of its proposed rulings and remedies; provided that such brief shall not contain or discuss any new evidence and shall not exceed ten pages. This page limitation shall apply... |
7. The Neutral shall rule on each disputed issue within 14 days following completion of the hearing. Such ruling shall adopt in its entirety the proposed ruling and remedy of one of the Parties on each disputed issue but may adopt one Party's proposed rulings and remedies on some issues and the other Party's proposed r... |
8. The Neutral shall be paid a reasonable fee plus expenses. These fees and expenses, along with the reasonable legal fees and expenses of the prevailing Party (including all expert witness fees and expenses), the fees and expenses of a court reporter, and any expenses for a hearing room, shall be paid as follows: |
a) If the Neutral rules in favor of one Party on all disputed issues in the ADR, the losing Party shall pay 100% of such fees and expenses. |
b) If the Neutral rules in favor of one Party on some issues and the other Party on other issues, the Neutral shall issue with the rulings a written determination as to how such fees and expenses shall be allocated between the Parties. The Neutral shall allocate fees and expenses in a way that bears a reasonable relati... |
9. The rulings of the Neutral and the allocation of fees and expenses shall be binding, non-reviewable, and non-appealable, and may be entered as a final judgment in any court having jurisdiction. |
10. Except as provided in paragraph 9 or as required by law, the existence of the Dispute, any settlement negotiations, the ADR proceeding, any submissions (including exhibits, testimony, proposed rulings, and briefs), and the rulings shall be deemed to be Confidential Information of both Parties. The Neutral shall hav... |
11. All ADR proceedings shall be conducted in the English language. |
12. Each Party shall have the right to be represented by counsel in all aspects of any ADR proceeding. |
Execution Copy |
88878677_21 |
DEVELOPMENT, EXCLUSIVITY AND OPTION PRODUCTS AGREEMENT |
By and between |
COLLPLANT LTD. |
AND |
ALLERGAN INDUSTRIE S.A.S. |
AND |
ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED |
TABLE OF CONTENTS |
Article 1 - DEFINITIONS .............................................................................................................. 2 |
Article 2 - DEVELOPMENT; RIGHT OF FIRST NEGOTIATION ........................................... 20 |
2.1 Development Plans ............................................................................................ 20 |
2.2 Conduct of Development Programs ................................................................... 20 |
2.3 Right of First Negotiation for Option Products ................................................. 22 |
2.4 No Additional Israel Innovation Authority Financing; Amendments of IIA Terms ........................................................................................................... 24 |
2.5 Supply Agreement ............................................................................................. 25 |
Article 3 - GOVERNANCE.......................................................................................................... 25 |
3.1 Joint Governance Committee............................................................................. 25 |
3.2 Responsibilities .................................................................................................. 25 |
3.3 Meetings and Minutes ........................................................................................ 26 |
3.4 Procedural Rules ................................................................................................ 26 |
3.5 Decision-Making ............................................................................................... 26 |
3.6 Interactions Between a Committee and Internal Teams .................................... 27 |
3.7 Expenses ............................................................................................................ 27 |
3.8 Authority ............................................................................................................ 27 |
Article 4 - EXCLUSIVITY RIGHTS ........................................................................................... 28 |
4.1 Grant of Exclusive Rights to AbbVie ................................................................ 28 |
4.2 Grant of Evaluation Rights to AbbVie .............................................................. 28 |
4.3 Limitations on CollPlant .................................................................................... 28 |
4.4 Covenant Not to Sue .......................................................................................... 28 |
4.5 Grant of Right of Reference to AbbVie ............................................................. 29 |
4.6 CollPlant Right to Sell OTC Skincare Products ................................................ 29 |
Article 5 - GENERAL PROVISIONS RELATING TO ACTIVITIES........................................ 29 |
5.1 AbbVie Development and Commercialization .................................................. 29 |
5.2 AbbVie Diligence Obligations........................................................................... 30 |
5.3 Compliance ........................................................................................................ 30 |
5.4 Subcontracting ................................................................................................... 30 |
5.5 Records and Audits ............................................................................................ 30 |
5.6 Cooperation ........................................................................................................ 31 |
Article 6 - FINANCIAL TERMS; PAYMENTS.......................................................................... 31 |
6.1 Upfront Fee ........................................................................................................ 31 |
6.2 Option Exercise Fee ........................................................................................... 31 |
6.3 Contingent Payments ......................................................................................... 32 |
6.4 Milestone Payments ........................................................................................... 32 |
6.5 Royalties ............................................................................................................ 35 |
6.6 Royalty Term ..................................................................................................... 36 |
6.7 Royalty Adjustments.......................................................................................... 36 |
6.8 Reports; Payment of Royalty ............................................................................. 37 |
6.9 Financial Records .............................................................................................. 38 |
6.10 Audit; Audit Dispute .......................................................................................... 38 |
6.11 Methods of Payments; Offsets ........................................................................... 39 |
6.12 Taxes .................................................................................................................. 39 |
6.13 Late Payments .................................................................................................... 40 |
6.14 Financial Obligations under In-License Agreements ........................................ 40 |
Article 7 - INTELLECTUAL PROPERTY RIGHTS .................................................................. 40 |
7.1 Ownership of Intellectual Property; Disclosure................................................. 40 |
7.2 Patent Prosecution and Maintenance ................................................................. 42 |
7.3 Enforcement of Patent Rights ............................................................................ 43 |
7.4 Infringement Claims by Third Parties ............................................................... 44 |
7.5 Invalidity or Unenforceability Defenses or Actions .......................................... 45 |
7.6 Product Trademarks ........................................................................................... 45 |
7.7 Inventor's Remuneration ................................................................................... 46 |
7.8 International Nonproprietary Name ................................................................... 46 |
Article 8 - CONFIDENTIALITY ................................................................................................. 46 |
8.1 Product Information ........................................................................................... 46 |
8.2 Confidentiality Obligations ............................................................................... 47 |
8.3 Permitted Disclosures. Each Party may disclose Confidential Information to the extent that such disclosure is: .............................................. 48 |
8.4 Use of Name ...................................................................................................... 49 |
8.5 Public Announcements ...................................................................................... 50 |
8.6 Publications ........................................................................................................ 50 |
8.7 Return of Confidential Information ................................................................... 50 |
8.8 Survival .............................................................................................................. 50 |
Article 9 - REPRESENTATIONS AND WARRANTIES ........................................................... 51 |
9.1 Representations and Warranties of Both Parties................................................ 51 |
9.2 Representations, Warranties and Covenants, as applicable, of CollPlant ......... 52 |
9.3 Mutual Covenants .............................................................................................. 56 |
9.4 Additional Covenants of CollPlant .................................................................... 56 |
9.5 Disclaimer .......................................................................................................... 57 |
9.6 Anti-Bribery and Anti-Corruption Compliance ................................................. 57 |
Article 10 - INDEMNIFICATION; INSURANCE ...................................................................... 57 |
10.1 Indemnification by AbbVie ............................................................................... 57 |
10.2 Indemnification by CollPlant ............................................................................. 58 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.